Trusted Resources: Education
Scientific literature and patient education texts
A Molecular Genetics View on Mucopolysaccharidosis Type II
source: Mutation research. Reviews in mutation research
authors: Verma S,Pantoom S,Petters J,Pandey AK,Hermann A,Lukas J
summary/abstract:Mucopolysaccharidosis Type II (MPS II) is an X-linked recessive genetic disorder that primarily affects male patients. With an incidence of 1 in 100,000 male live births, the disease is one of the orphan diseases. MPS II symptoms are caused by mutations in the lysosomal iduronate-2-sulfatase (IDS) gene. The mutations cause a loss of enzymatic performance and result in the accumulation of glycosaminoglycans (GAGs), heparan sulfate and dermatan sulfate, which are no longer degradable. This inadvertent accumulation causes damage in multiple organs and leads either to a severe neurological course or to an attenuated course of the disease, although the exact relationship between mutation, extent of GAG accumulation and disease progression is not yet fully understood. This review is intended to present current diagnostic procedures and therapeutic interventions. In times when the genetic profile of patients plays an increasingly important role in the assessment of therapeutic success and future drug design, we chose to further elucidate the impact of genetic diversity within the IDS gene on disease phenotype and potential implications in current diagnosis, prognosis and therapy. We report recent advances in the structural biological elucidation of I2S enzyme that that promises to improve our future understanding of the molecular damage of the hundreds of IDS gene variants and will aid damage prediction of novel mutations in the future.
organization: Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Gehlsheimer Str. 20, 18147, Rostock, Germany; National Institute of Malarial Research, Indian Council of Medical Research, New Delhi, 110077, India.DOI: 10.1016/j.mrrev.2021.108392
read more
Related Content
-
Emotional Responses to Diagnosis of MPS or MLIf you or someone you know have been dia...
-
Oxidative Stress in Mucopolysaccharidoses: Pharmacological ImplicationsAlthough mucopolysaccharidoses (MPS) are...
-
Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities fo...Mucopolysaccharidosis type II (MPS II) r...
-
Mucopolysaccharidosis II (MPS II) in a Free-Living Kaka (Nestor Meridionalis) in New ZealandA lysosomal storage disease, identified ...
-
Expanding the Phenotype of Mucopolysaccharidosis Type II RetinopathyPurpose: To report novel retinal finding...
-
Mucopolysaccharidosis Conditions Explainedhttps://www.youtube.com/watch?v=EmSJ_hGE...
-
Oral Treatment for Mucopolysaccharidosis VI: Outcomes of the First Phase Iia Study With OdiparcilMucopolysaccharidosis (MPS) disorders ar...